A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
about
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligandsChemistry and structural biology of androgen receptorEndocrine treatment in prostate cancerAn evaluation of bicalutamide in the treatment of prostate cancer.Bicalutamide (Casodex) in the treatment of prostate cancer.Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.The treatment of prostate cancer: an overview of current options.Recent advances in the development of selective androgen receptor modulators.Androgen induction of prostate cancer cell invasion is mediated by ezrin.An update on bicalutamide in the treatment of prostate cancer.A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.Androgen Deprivation for Prostatic Carcinoma: A Rationale for Choosing Components
P2860
Q24680373-227275B2-1CA1-485F-9AFE-4B6DA37F0105Q24685498-05835D23-7EB5-4AA2-8A31-B342C5F1CDD5Q28378298-9E98DDC3-F69A-4928-AEAC-2FF2F9B2FBB3Q34145167-43B525AB-F678-48AD-B83C-A4469C610AABQ34293191-BCE5DE32-E14A-4B98-BBD9-C06B0F4D9886Q34394508-80039B7F-47E7-4E91-986E-28CC06998D76Q34441487-98468262-C8A2-4C6A-B506-90B185617CB0Q34452166-07EF489B-FCD3-46B3-9DF8-A46C332E7C19Q34552438-0913790E-1022-48B1-8D44-8D8C68CCBD4BQ34985529-17F57322-EAD0-4554-9B31-ADF86DC32A78Q40250668-3E544A50-922D-4D77-8085-AB1634337877Q44911730-0CAB841A-2911-4027-95CA-34173CFBBA01Q45101314-C0224B91-7117-4C89-839B-2995DB0DD2D7Q46708843-AF55E12B-29ED-4EE6-B4FF-DD205AC13AA1Q53989501-25388F37-27EF-47F0-99C6-378D1D9C712AQ56672866-E18165D5-683B-4060-ACD9-52AF21B2837F
P2860
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
A controlled trial of bicaluta ...... sodex Combination Study Group.
@en
A controlled trial of bicaluta ...... sodex Combination Study Group.
@nl
type
label
A controlled trial of bicaluta ...... sodex Combination Study Group.
@en
A controlled trial of bicaluta ...... sodex Combination Study Group.
@nl
prefLabel
A controlled trial of bicaluta ...... sodex Combination Study Group.
@en
A controlled trial of bicaluta ...... sodex Combination Study Group.
@nl
P2093
P1433
P1476
A controlled trial of bicaluta ...... sodex Combination Study Group.
@en
P2093
Kolvenbag G
Patterson AL
Schellhammer P
Vogelzang N
P304
P356
10.1016/S0090-4295(99)80077-6
P407
P577
1995-05-01T00:00:00Z